Nkarta (NKTX) Competitors $1.83 +0.03 (+1.67%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.80 -0.03 (-1.86%) As of 07/11/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKTX vs. VALN, BCAX, PGEN, SIGA, ATYR, ORKA, CAPR, CGEM, MREO, and KMDAShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Valneva (VALN), Bicara Therapeutics (BCAX), Precigen (PGEN), Siga Technologies (SIGA), aTyr Pharma (ATYR), Oruka Therapeutics (ORKA), Capricor Therapeutics (CAPR), Cullinan Therapeutics (CGEM), Mereo BioPharma Group (MREO), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Its Competitors Valneva Bicara Therapeutics Precigen Siga Technologies aTyr Pharma Oruka Therapeutics Capricor Therapeutics Cullinan Therapeutics Mereo BioPharma Group Kamada Valneva (NASDAQ:VALN) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Does the media favor VALN or NKTX? In the previous week, Valneva had 1 more articles in the media than Nkarta. MarketBeat recorded 4 mentions for Valneva and 3 mentions for Nkarta. Nkarta's average media sentiment score of 1.06 beat Valneva's score of 0.72 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, VALN or NKTX? Valneva has higher revenue and earnings than Nkarta. Valneva is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioValneva$183.52M2.81-$13.25M-$1.19-5.10NkartaN/AN/A-$108.79M-$1.51-1.21 Is VALN or NKTX more profitable? Nkarta has a net margin of 0.00% compared to Valneva's net margin of -43.08%. Nkarta's return on equity of -26.64% beat Valneva's return on equity.Company Net Margins Return on Equity Return on Assets Valneva-43.08% -43.05% -16.23% Nkarta N/A -26.64%-21.62% Which has more risk and volatility, VALN or NKTX? Valneva has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Do insiders & institutionals believe in VALN or NKTX? 11.4% of Valneva shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 14.9% of Valneva shares are owned by company insiders. Comparatively, 8.4% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend VALN or NKTX? Valneva presently has a consensus price target of $15.50, indicating a potential upside of 155.35%. Nkarta has a consensus price target of $14.33, indicating a potential upside of 683.24%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Nkarta 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13 SummaryNkarta beats Valneva on 9 of the 16 factors compared between the two stocks. Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.85M$2.94B$5.56B$9.10BDividend YieldN/A2.41%5.06%4.02%P/E Ratio-1.2120.8528.2620.26Price / SalesN/A263.32427.70153.06Price / CashN/A42.1137.1257.67Price / Book0.327.638.045.49Net Income-$108.79M-$55.05M$3.19B$250.45M7 Day Performance4.27%8.43%3.62%4.79%1 Month Performance-1.61%8.14%5.98%9.59%1 Year Performance-71.89%1.62%29.39%16.41% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta1.8025 of 5 stars$1.83+1.7%$14.33+683.2%-71.9%$129.85MN/A-1.21140News CoveragePositive NewsVALNValneva1.8002 of 5 stars$5.75-1.0%$15.50+169.6%-20.0%$494.40M$183.52M-4.83700News CoverageBCAXBicara Therapeutics2.1424 of 5 stars$9.01-0.2%$31.86+253.6%N/A$492.46MN/A0.0032PGENPrecigen4.107 of 5 stars$1.59-1.9%$6.00+277.4%+13.7%$478.19M$3.92M-2.84190Positive NewsAnalyst UpgradeSIGASiga Technologies2.246 of 5 stars$6.73+0.6%N/A-22.4%$477.94M$138.72M10.0440News CoverageOptions VolumeATYRaTyr Pharma2.0952 of 5 stars$5.30-0.2%$20.20+281.1%+204.6%$472.61M$230K-6.5453Gap DownHigh Trading VolumeORKAOruka Therapeutics2.9071 of 5 stars$13.29+5.5%$40.38+203.8%N/A$471.75MN/A-2.95N/APositive NewsCAPRCapricor Therapeutics2.5454 of 5 stars$9.90-3.4%$32.22+225.5%+73.6%$468.19M$22.27M-6.97101Trending NewsAnalyst ForecastGap DownCGEMCullinan Therapeutics1.6897 of 5 stars$7.42-5.0%$30.00+304.3%-53.2%$460.90MN/A-2.5530News CoverageMREOMereo BioPharma Group1.5651 of 5 stars$2.92+1.7%$7.60+160.3%-61.2%$456.33M$10M-41.7140News CoverageAnalyst ForecastGap UpHigh Trading VolumeKMDAKamada4.2241 of 5 stars$7.71-2.2%$13.00+68.6%+24.8%$453.14M$160.95M26.59360 Related Companies and Tools Related Companies Valneva Competitors Bicara Therapeutics Competitors Precigen Competitors Siga Technologies Competitors aTyr Pharma Competitors Oruka Therapeutics Competitors Capricor Therapeutics Competitors Cullinan Therapeutics Competitors Mereo BioPharma Group Competitors Kamada Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NKTX) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKTX Stock Alerts